Amoxapine

CHEMBL1113 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

313.8 g/mol

LogP

2.6

Phase

4

A tetracyclic antidepressant that blocks reuptake of norepinephrine and serotonin while also antagonizing dopamine receptors, giving it both antidepressant and mild antipsychotic properties. It is used to treat depression, particularly when psychotic features are present.

Masse moléculaire

313,8000 g/mol

LogP

2,60

TPSA

36,90 Å²

Règle des 5 de Lipinski

Conforme

Mécanisme d'action

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2

InChI

InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2

Molecular Formula

C17H16ClN3O

HBD / HBA

1 / 3

Liaisons Rotatives

1

Atomes Lourds

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A tetracyclic antidepressant that blocks reuptake of norepinephrine and serotonin while also antagonizing dopamine receptors, giving it both antidepressant and mild antipsychotic properties. It is used to treat depression, particularly when psychotic features are present.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Amoxapine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1113. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 2170. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Amoxapine sur PillFYI

Structure

Données Clés

Formule: C17H16ClN3O

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.